Treatment Archives - Bay Area Lyme Foundation

Bay Area Lyme Foundation Issues Call-for-Applications for 2027 Emerging Leader Awards and Research Grants

By Bay Area Lyme Foundation

FOR IMMEDIATE RELEASE

Bay Area Lyme Foundation Issues Call-for-Applications for 2027 Emerging Leader Awards and Research Grants

2027 program offers two $150,000 grants to advance the development of diagnostics and therapeutics for Lyme and tick-borne illnesses

PORTOLA VALLEY, Calif., October 20, 2026 – Bay Area Lyme Foundation, a leading sponsor of Lyme disease research in the US, today announced the opening of applications for the 2027 Emerging Leader Awards (ELA), which recognize researchers identifying innovative approaches to solve the challenges of Lyme and tick-borne illnesses. These awards provide funding and mentorship for scientists at the postdoctoral level through associate professor level who seek to advance novel methodologies that could change the future of diagnosis and treatment of Lyme and tick‑borne diseases.

“Lyme disease continues to be difficult to diagnose and often impossible to cure, particularly when patients have co-infections,” said Katariina Tuovinen, research grant director at Bay Area Lyme Foundation. “Through the Emerging Leader Awards, we hope to inspire and support promising scientists who are pursuing innovative research that has the potential to benefit current or future patients with tick-borne illnesses.”

The two 2027 ELAs, each consisting of a $150,000 grant, are:

Lyme Disease Award will support creative approaches to advancing diagnostics and/or therapeutics for Lyme disease, continuing the legacy started more than a decade ago.
Tick-borne Infection Award will fund research on non-Borrelia tick-borne pathogens/infections occurring in the US, with preference for bacterial and parasitic pathogens. Projects may address single infections or co-infections in combination with Borrelia burgdorferi.

While the awards are open to academic and private sector researchers working in any scientific area related to tick-borne disease, those seeking to advance diagnostics or therapeutics for Lyme and other tick-borne illnesses are particularly encouraged to apply. Applications are due by February 1, 2027.

Richard Horowitz, MD: Ending Chronic Illness

By Bay Area Lyme Foundation

Richard Horowitz, MD

Dr. Richard Horowitz is a board-certified internist, bestselling author, and medical director of the Hudson Valley Healing Arts Center. Over 42 years, he has treated more than 13,000 Lyme and tick-borne disease patients and advised HHS, the New York State Department of Health, and agencies worldwide. He pioneered the MSIDS model and has published peer-reviewed work on short-term oral generic protocols that have put many patients into long-term remission, including reversal of the Alzheimer’s biomarker p-tau 217. His third book, Ending Chronic Illness (Simon & Schuster, October 2026), applies that 16-point model to the prevention and treatment of most chronic illnesses, from Alzheimer’s, autism, and cancer to cardiovascular disease, ME/CFS, and chronic infections. More: https://cangetbetter.com

Watch Now

Bay Area Lyme Ventures Invests in LymeLess Health to Accelerate AI-Powered Innovation for Lyme & Tick-Borne Disease Patients

By Bay Area Lyme Foundation

FOR IMMEDIATE RELEASE

Bay Area Lyme Ventures Invests in LymeLess Health to Accelerate AI-Powered Innovation for Lyme & Tick-Borne Disease Patients

Investment supports launch of AI care companion, Ella, designed to help Lyme+ patients navigate diagnosis, treatment, and long-term disease management

PORTOLA VALLEY, Calif., August 22, 2026 — Bay Area Lyme Ventures, Bay Area Lyme Foundation’s venture philanthropy initiative devoted to advancing solutions for Lyme disease, today announced that it has invested in LymeLess Health , an AI-powered digital health company focused on transforming how people with Lyme disease navigate diagnosis, treatment, and long-term care. The announcement coincides with the launch of LymeLess’ patient app powered by Ella, an intelligent AI health companion designed specifically for Lyme and tick-borne disease (Lyme+) patients.

The investment reflects Bay Area Lyme Ventures mission to accelerate promising innovations that have the potential to improve the lives of Lyme disease patients by advancing new diagnostics, therapeutics, digital health technologies, and data-driven approaches to care.

“People with Lyme disease often spend months or years searching for answers while trying to manage an extraordinarily complex illness,” said Linda Giampa, founder and managing director of Bay Area Lyme Ventures. “Bay Area Lyme Ventures was created to help accelerate innovations that can change that trajectory. LymeLess combines patient experience, artificial intelligence, and real-world data in a way that has the potential to empower patients while generating insights that could ultimately advance research across the Lyme disease field.”

Organ-On-A-Chip: Restoring a Patient’s Ability to Fight Back Against Lyme

By Bay Area Lyme Foundation

Bay Area Lyme Leading the Way series

Our 2026 LymeAid Fund-A-Need supported Girija Goyal, PhD, at Harvard’s Wyss Institute, whose groundbreaking lymph node chip models human immune responses to Lyme disease, accelerating the development of personalized therapies and potentially restoring a patient’s ability to fight back against Lyme. This technology was recently highlighted in NASA Artemis-related organ chip research.

NASA is using organ-on-a-chip technologies to study human biology in space.

This breakthrough technology allows investigator Girija Goyal, PhD, at Harvard’s Wyss Institute to recreate key aspects of the human immune system on a tiny chip—a pioneering approach leveraging human biology rather than traditional animal models. Using her lymphoid organ chip, Dr. Goyal has identified one way Lyme bacteria appear to evade the immune system.

This is not research repurposed from another disease. It is a fundamentally new approach aimed at enabling the body’s natural ability to fight infection. It is Lyme-focused science built from the ground up and tested from the start in a human system designed by the scientist leading the work. Its promise is so significant that organizations like NASA are using similar organ-on-a-chip technologies to study human biology in space.

New Bay Area Lyme Foundation Study Shows Common FDA-Cleared Lyme Tests Miss 64-78% of Early Cases, Underscores Urgent Need for Improved Diagnostics

By Bay Area Lyme Foundation

FOR IMMEDIATE RELEASE

New Bay Area Lyme Foundation Study Shows Common FDA-Cleared Lyme Tests Miss 64-78% of Early Cases, Underscores Urgent Need for Improved Diagnostics

Research published in the Journal of Clinical Microbiology

PORTOLA VALLEY, Calif., April 21, 2026 –Bay Area Lyme Foundation, a national nonprofit and leading sponsor of tick-borne disease research in the US, today announced the publication of new research in the Journal of Clinical Microbiology based on data from its Lyme Disease Biobank. The study found that the commonly used FDA-cleared diagnostic testing methods available to providers and major national diagnostic laboratories are highly insensitive and miss 64-78% of early Lyme disease cases, including those who present with the characteristic erythema migrans (EM) Lyme rash.

“This study demonstrates that common two-tiered Lyme tests, utilized for decades, often fail to detect early Lyme disease and are leaving patients behind, highlighting a critical need for improved medical education on the limitations of current diagnostics,” said Liz Horn, PhD, MBI, Principal Investigator of Lyme Disease Biobank and lead author of the study. “Our findings also add to the evidence that improved diagnostics, ideally those that directly detect the bacteria that cause Lyme disease, are urgently needed.”

This large-scale, head-to-head study comparing 2 standard two-tiered testing (STTT) and 2 modified two-tiered testing (MTTT) diagnostic algorithms (the commonly used Lyme disease diagnostic algorithms) confirms that the sensitivity of two-tiered testing algorithms is low among patients with early infection. For the 107 early Lyme disease cases evaluated, the various testing algorithms missed 64-78% of early Lyme cases. Overall, only 39% (42/107) of participants with early Lyme disease were STTT or MTTT positive by any of the 4 algorithms.

Improving Lyme Diagnostics, Biomarkers, and Treatment: Inside Dr. Peter Gwynne’s Research

By Bay Area Lyme Foundation

Bay Area Lyme Leading the Way series

“I wanted to be doing work that was driven by clinical need… and there are a lot of clinical needs in Lyme disease.”

– Peter Gwynne, PhD

For too many people with Lyme disease, the journey begins with uncertainty. A missed rash. A negative test. Symptoms that don’t make sense. A diagnosis that comes too late, or not at all. Bay Area Lyme Foundation believes this must change. And we believe change happens through funding rigorous science, innovative thinking, and supporting researchers willing to tackle the hardest questions head-on.

One of those scientists is Tufts researcher Peter Gwynne, PhD, a microbiologist whose work sits at the cutting edge of Lyme research and is the recipient of our 2022 Emerging Leader Award. We spoke with Dr. Gwynne to get an inside look at his work and understand how this may impact Lyme patients in the future. His focus is simple to state but complex to achieve: develop better diagnostics, identify meaningful biomarkers, and move the field toward treatments and even prevention strategies that could fundamentally reshape how Lyme disease is understood and managed.

Drawn to Lyme by the Urgency of the Need

Dr. Gwynne did not begin his career in Lyme disease. He trained in molecular microbiology, studying pathogens such as Salmonella and Staphylococcus, the bacteria responsible for serious infections, including those often acquired in hospital settings. But over time, he found himself seeking work that could make a tangible difference for patients.

We Need a New Generation of Lyme Doctors: James Bruzzese, MD, is Leading the Way

By Bay Area Lyme Foundation

Bay Area Lyme Spotlights Series

“Some institutions are evolving in research and education, but it’s not translating to clinical practice.”

– James Bruzzese, MD

When James Bruzzese, MD, talks about Lyme disease, he doesn’t speak in abstractions. He speaks as a brother who watched his sister lose her ability to walk; a son who watched his father leave his job to become a full-time caregiver; and as a medical student who sat in lecture halls knowing that what was being taught about Lyme and tick-borne disease was grossly incomplete.

Now, as a young physician preparing to open a practice dedicated to treating Lyme and tick-borne disease patients in New York, James represents something the Lyme community urgently needs: a new generation of doctors who understand that Lyme is real, that patients deserve better, and that the status quo must be challenged.

“It Was Traumatic. We Thought We Might Lose Her.”

Bacterial Mechanism That Could Help Prevent and Treat Lyme Arthritis Identified by New Bay Area Lyme Foundation–Supported Study

By Bay Area Lyme Foundation

FOR IMMEDIATE RELEASE

Bacterial Mechanism That Could Help Prevent and Treat Lyme Arthritis Identified by New Bay Area Lyme Foundation–Supported Study

Research published in PLOS Pathogens highlights a cell wall–driven trigger of joint inflammation, pointing to new ways to target Lyme arthritis

PORTOLA VALLEY, Calif., January 20, 2026 — Bay Area Lyme Foundation, a leading sponsor of Lyme disease research in the United States, announced the publication of new research in PLOS Pathogens identifying a novel mechanism that may trigger Lyme arthritis, one of the most common and debilitating complications of Lyme disease in the US. The study provides new insight into how the structure of Borrelia burgdorferi peptidoglycan, a component of the bacterium’s cell wall, and its interaction with a Borrelia protein can provoke joint inflammation. In a preclinical model, subtle changes researchers made to the bacterium’s peptidoglycan structure nearly eliminated arthritis despite ongoing infection, suggesting new approaches to reduce Lyme arthritis and joint damage that may complement antibiotics by targeting inflammatory bacterial components.

“Understanding how these bacterial structures provoke inflammation is an avenue towards new approaches for limiting long-term joint damage and possibly treating patients whose symptoms persist despite standard antibiotic therapy,” said Brandon L. Jutras, PhD, lead author of the study and associate professor of Microbiology-Immunology at Northwestern University Feinberg School of Medicine, and a Bay Area Lyme Foundation 2021 Emerging Leader Award winner. “Our findings offer critical insight into how Lyme arthritis is largely driven by specific structural components of Borrelia burgdorferi that may be targeted independent of the other aspects of the infection.”

This new study demonstrates that the chemical makeup and physical structure of peptidoglycan, a structural component of the Borrelia cell wall, play a decisive role in determining whether joint inflammation develops. It also demonstrates how impeding peptidoglycan’s interaction with a specific Borrelia protein may impact the bacterium’s ability to migrate to and persist within joint tissue, resulting in near elimination of Lyme arthritis in the study.

A New Year Call to Action After December 15, 2025, HHS Roundtable

By Bay Area Lyme Foundation

Bay Area Lyme Spotlight Series

By Charlotte Mao, MD, MPH, Bay Area Lyme Foundation

“Chronic Lyme Disease patients have been ignored for too long. That must end now.”

– Charlotte Mao, MD, MPH

A Long-Overdue Moment of Recognition

Starting in 2026, Lyme disease and other tick-borne disease patients and their families have some reason to be encouraged by the growing recognition of the realities they face and the prospect of continued research to support new diagnostics and treatments.

The December 15, 2025, Department of Health and Human Services (HHS) roundtable marked something rare and long overdue: federal recognition of patient need, grounded in scientific evidence presented by researchers, clinicians, and patient advocates. But patients need more than another moment of recognition. They need results. In 2026, the question is whether that recognition will translate into sustained action, measurable progress, and real improvements in care.

Accelerating Breakthroughs, Advancing Hope: How Bay Area Lyme Powers Lyme Disease Research

By Bay Area Lyme Foundation

Bay Area Lyme Leading the Way Series

“Every one of our success stories amplifies the ripple effect of philanthropy done right: targeted, strategic, and driven by measurable impact.”

– Katariina Tuovinen

For more than a decade, Bay Area Lyme Foundation has been rewriting the story of Lyme and tick-borne disease research. With a mission to make Lyme disease easy to diagnose and simple to cure, the Foundation has built a national reputation as a nimble, entrepreneurial engine for scientific innovation. Since its founding in 2012, Bay Area Lyme has invested more than $31 million to support over 60 groundbreaking studies and partnerships across 56 institutions nationwide, each one helping to transform the landscape of Lyme disease diagnostics, treatments, and prevention.

At the heart of this success lies a small but mighty force: The Bay Area Lyme Science Committee, led by Research Grant Director Katariina Tuovinen, MS, MBA, MA, together with pediatric infectious disease physician Charlotte Mao, MD, MPH, and Liz Horn, PhD, MBI, Principal Investigator of Lyme Disease Biobank. Together, this team guides a grantmaking strategy that prizes bold ideas, cross-disciplinary collaboration, and measurable impact—an approach that has introduced new talent, fresh perspectives, and innovative technologies to a field that desperately needs them.